{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-030025","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.674988+00:00","generated_at":"2026-06-27T02:02:15.817277+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NextCure reports FY 2021 net loss of $69.4M; cash $219.6M, expects funding into Q1 2024","bullets":["Net loss $69.4M in 2021 vs $36.6M in 2020; no revenue recognized (Eli Lilly agreement ended).","Cash, equivalents, marketable securities $219.6M at Dec 31, 2021, down $63.8M; expected to fund ops into Q1 2024.","R&D expenses $50.2M in 2021 vs $46.6M; G&A $20.6M vs $17.0M primarily from headcount increases.","Multiple 2022 data readouts planned: NC318 Phase 2 update Q4, NC410 update H2, NC762 initial Phase 1 data H2, NC525 IND filing Q4.","COVID-19 pandemic delayed clinical trial enrollment, causing some milestones to be pushed back."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-030025","json":"https://secwatch.observer/filing/0001104659-22-030025.json","markdown":"https://secwatch.observer/filing/0001104659-22-030025.md","text":"https://secwatch.observer/filing/0001104659-22-030025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465922030025/0001104659-22-030025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465922030025/tm228329d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:02:15.817277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}